CA64082X2032
© Newsfile
10.09.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage today announces the results of its Annual General Meeting of Shareholders ("AGM")...
Themefolio
Profiler
Peergroup
© Newsfile
19.08.2021
NGEN
LISTED
TSX
NervGen Pharma Provides an Operational Update on Its Ongoing Phase 1 Clinical Trial and Reports Second Quarter 2021 Results
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 19, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today is providing an update on its Phase I clinical trial and is reporting its fin...
Themefolio
Profiler
Peergroup
© Newsfile
09.08.2021
NGEN
LISTED
TSX
NervGen Pharma and Massachusetts General Hospital Collaborate on Preclinical Studies in Alzheimer's Disease
News Preview
Dr. Ksenia Kastanenka to Study NVG-291's Potential to Promote Repair in Alzheimer's Disease ModelsVancouver, British Columbia--(Newsfile Corp. - August 9, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous sys...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
05.08.2021
NGEN
LISTED
TSX
NervGen Pharma Corp. Closes Non-Brokered Private Placement
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - August 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, i...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
17.07.2021
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced that the Company has granted 125,000 incentive stock options to existin...
Themefolio
Profiler
Peergroup
© Newsfile
15.07.2021
NGEN
LISTED
TSX
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board
News Preview
NervGen Supports World Brain Day on July 22 to "Stop Multiple Sclerosis"Vancouver, British Columbia--(Newsfile Corp. - July 15, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced...
Themefolio
Profiler
Peergroup
© Newsfile
12.07.2021
NGEN
LISTED
TSX
NervGen Pharma Expands Alzheimer's Disease Scientific Advisory Board
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, today announced the addition of three world-class scientists and clinical researc...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2021
NGEN
LISTED
TSX
NervGen Engages Vorticom Inc. to Provide Media Relations Services
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced that it has engaged Vorticom Inc. ("Vorticom"), a New York based full-service...
Themefolio
Profiler
Peergroup
© Newsfile
10.06.2021
NGEN
LISTED
TSX
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
News Preview
NervGen Preparing for Upcoming Phase 1b Clinical Trial in Alzheimer's DiseaseVancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2021
NGEN
LISTED
TSX
NervGen Pharma Reports First Quarter 2021 Results
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system injuries, today reported its financial results for the first quarter ended March 31, 2021."We...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, announced that it has closed its previously announced overnight, "best eff...
Themefolio
Profiler
Peergroup
© Newsfile
12.05.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - May 12, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerat...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
08.05.2021
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, today announced that the Company has granted 800,000 incentive stock options to a...
Themefolio
Profiler
Peergroup
© Newsfile
06.05.2021
NGEN
LISTED
TSX
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative treatments for nerve damage and neurodegenerative diseases, is pleased to announce today that the first subject has been dosed with NVG-291 i...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Pricing of Overnight Marketed Equity Offering
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative dise...
Themefolio
Profiler
Peergroup
© Newsfile
04.05.2021
NGEN
LISTED
TSX
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announced that it has launched an overnight, "best efforts" marketed public offering...
Themefolio
Profiler
Peergroup
© Newsfile
04.05.2021
NGEN
LISTED
TSX
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
News Preview
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESVancouver, British Columbia--(Newsfile Corp. - May 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative d...
Themefolio
Profiler
Peergroup
© Newsfile
24.04.2021
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 306,000 incentive stock opti...
Themefolio
Profiler
Peergroup
© Newsfile
22.04.2021
NGEN
LISTED
TSX
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 22, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce the appointment of Daniel Mikol, MD, PhD, as the Company...
Themefolio
Profiler
Peergroup
© Newsfile
14.04.2021
NGEN
LISTED
TSX
NervGen Pharma Receives Ethics Approval to Initiate Phase 1 Clinical Trial for NVG-291
News Preview
Remains on Track to Dose First Subjects in Q2 2021Vancouver, British Columbia--(Newsfile Corp. - April 14, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, has received approval and gui...
Themefolio
Profiler
Peergroup
© Newsfile
08.04.2021
NGEN
LISTED
TSX
NervGen Pharma Reports 2020 Year End Results
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020....
Themefolio
Profiler
Peergroup
© Newsfile
08.03.2021
NGEN
LISTED
TSX
NervGen Pharma Receives Orphan Designation from the European Medicines Agency for NVG-291 for the Treatment of Spinal Cord Injury
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 8, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the European Medicines Agency ("EMA") has granted Orphan D...
Themefolio
Profiler
Peergroup
© Newsfile
04.03.2021
NGEN
LISTED
TSX
NervGen Pharma Provides Regulatory Update on Development Program For NVG-291
News Preview
Plans to Dose First Human Subjects in Phase 1 in Q2 2021Vancouver, British Columbia--(Newsfile Corp. - March 4, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided a regulat...
Themefolio
Profiler
Peergroup
© Newsfile
27.01.2021
NGEN
LISTED
TSX
NervGen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 27, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will add an Alzheimer's disease patient cohort...
Themefolio
Profiler
Peergroup
© Newsfile
26.01.2021
NGEN
LISTED
TSX
NervGen Pharma Establishes Alzheimer's Disease Scientific Advisory Board
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer's Disease Scientific Advisory...
Themefolio
Profiler
Peergroup
© Newsfile
05.01.2021
NGEN
LISTED
TSX
NervGen to Present at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that Paul Brennan, President & CEO, will conduct a corpora...
Themefolio
Profiler
Peergroup
© Newsfile
15.12.2020
NGEN
LISTED
TSX
NervGen Pharma Engages CRO for Phase 1 Clinical Trial
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 15, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has engaged Novotech (Australia) Pty Limited (...
Themefolio
Profiler
Peergroup
© Newsfile
19.11.2020
NGEN
LISTED
TSX
NervGen Pharma Reports Third Quarter 2020 Results and Provides Operational Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the third quarter ended September 3...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2020
NGEN
LISTED
TSX
NervGen Pharma Retains Dr. George Perry to Advise on Alzheimer's Disease Program and Renews Business Advisory Relationship with Brian McAlister
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has retained George Perry, PhD, the current and fo...
Themefolio
Profiler
Peergroup
© Newsfile
28.10.2020
NGEN
LISTED
TSX
NervGen Pharma Appoints Randall E. Kaye, MD to the Board of Directors and Provides Operational Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it has appointed Dr. Randall Kaye to the Company's Board...
Themefolio
Profiler
Peergroup
© Newsfile
19.10.2020
NGEN
LISTED
TSX
NervGen Pharma Engages Dr. Michael Davis, Former Director of the U.S. Combat Casualty Care Research Program, to Advise on Strategic Development Targets and Non-Dilutive Funding Sources For NVG-291
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today is pleased to announce that it has retained the services of Michael Dav...
Themefolio
Profiler
Peergroup
© Newsfile
02.10.2020
NGEN
LISTED
TSX
NervGen Pharma Provides Company Update and Announces Results of Annual General Meeting of Shareholders
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, provided an update on the development plans for its lead compound, NVG-2...
Themefolio
Profiler
Peergroup
© Newsfile
22.09.2020
NGEN
LISTED
TSX
NervGen Pharma Announces Annual General Meeting and Company Update to Be Held on September 30, 2020
News Preview
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that it will host its annual general meeting of shareholde...
Themefolio
Profiler
Peergroup
© Newsfile
10.09.2020
NGEN
LISTED
TSX
NervGen Pharma Announces Departure of Chief Operating Officer
News Preview
LifeSci Advisors Engaged to Provide Investor Relations ServicesVancouver, British Columbia--(Newsfile Corp. - September 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announ...
Themefolio
Profiler
Peergroup
© Newsfile
21.08.2020
NGEN
LISTED
TSX
NervGen Pharma Reports Second Quarter 2020 Results
News Preview
Phase 1 Clinical Study Remains on Track for Q4 2020Vancouver, British Columbia--(Newsfile Corp. - August 21, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financia...
Themefolio
Profiler
Peergroup
© Newsfile
10.08.2020
NGEN
LISTED
TSX
NervGen Pharma Corp. Completes $6.45 Million Public Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 10, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that today it has closed its previously announced "best efforts" public...
Themefolio
Profiler
Peergroup
© Newsfile
04.08.2020
NGEN
LISTED
TSX
NervGen Pharma Corp. Announces Upsizing of Financing and Filing of Amended and Restated Prospectus Supplement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 4, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, announces that it has increased the size of its previously announced common share...
Themefolio
Profiler
Peergroup
© Newsfile
30.07.2020
NGEN
LISTED
TSX
NervGen Pharma Corp. Announces Filing of Prospectus Supplement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announces that the Company has filed a prospectus supplement (the "Prospectus...
Themefolio
Profiler
Peergroup
© Newsfile
27.07.2020
NGEN
LISTED
TSX
NervGen Pharma Announces Pricing of Public Offering
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 27, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has priced its previously announced offering of eq...
Themefolio
Profiler
Peergroup
© Newsfile
22.06.2020
NGEN
LISTED
TSX
NervGen Pharma to Collaborate on Chronic Spinal Cord Injury Study Sponsored by the State of Ohio
News Preview
Ohio Department of Higher Education Awards $250,000 Grant To Dr. Jerry Silver, Co-inventor of NervGen's Lead CompoundVancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of ne...
Themefolio
Profiler
Peergroup
© Newsfile
03.06.2020
NGEN
LISTED
TSX
NervGen Pharma Grants Stock Options
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced that the Company has granted 225,000 incentive stock option...
Themefolio
Profiler
Peergroup
© Newsfile
01.06.2020
NGEN
LISTED
TSX
NervGen Pharma Reports First Quarter 2020 Results
News Preview
Phase 1 Clinical Trial Remains on Track for Q4 2020Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial r...
Themefolio
Profiler
Peergroup
© Newsfile
20.05.2020
NGEN
LISTED
TSX
NervGen Pharma Corp. Closes Non-Brokered Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 20, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, is pleased to announce that it has closed a non-brokered private placement of 1,8...
Themefolio
Profiler
Peergroup
© Newsfile
29.04.2020
NGEN
LISTED
TSX
NervGen Pharma Reports 2019 Year End Results
News Preview
Phase 1 Clinical Study Remains on Track for Q4 2020Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its fin...
Themefolio
Profiler
Peergroup
© Newsfile
06.04.2020
NGEN
LISTED
TSX
NervGen Pharma Provides a Corporate Update in Response to the COVID-19 Pandemic; Announces Upcoming Presentation at Solebury Trout Virtual Investor Conference on April 7th
News Preview
Phase 1 Clinical Study Remains on Track for Q4 2020Vancouver, British Columbia--(Newsfile Corp. - April 6, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today provided an update on i...
Themefolio
Profiler
Peergroup
© Newsfile
27.02.2020
NGEN
LISTED
TSX
NervGen Pharma Provides a Development Update on Its Lead Product NVG-291
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 26, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today is providing an update to its development plan for its lead program, NVG-291. These cha...
Themefolio
Profiler
Peergroup
© Newsfile
24.02.2020
NGEN
LISTED
TSX
NervGen Pharma Appoints Bill Adams as Chief Financial Officer
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, today announced the appointment of Mr. William (Bill) Adams, CPA, CA, to the position of Chie...
Themefolio
Profiler
Peergroup
© Newsfile
13.01.2020
NGEN
LISTED
TSX
NervGen Pharma Responds to Recent Increase in Market Activity
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material c...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
